Eventide Asset Management LLC Sells 119,208 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Eventide Asset Management LLC lowered its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 23.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 380,000 shares of the company’s stock after selling 119,208 shares during the period. Eventide Asset Management LLC owned 0.94% of Keros Therapeutics worth $22,067,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. acquired a new position in shares of Keros Therapeutics during the second quarter worth $1,118,000. Bank of New York Mellon Corp raised its stake in Keros Therapeutics by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after buying an additional 18,755 shares during the last quarter. SG Americas Securities LLC bought a new position in Keros Therapeutics during the second quarter worth $532,000. American Century Companies Inc. raised its stake in Keros Therapeutics by 24.9% during the second quarter. American Century Companies Inc. now owns 298,170 shares of the company’s stock worth $13,626,000 after buying an additional 59,364 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Analyst Ratings Changes

KROS has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Wedbush reaffirmed an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Bank of America decreased their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Guggenheim began coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target for the company. Finally, Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating for the company. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $88.89.

Keros Therapeutics Stock Up 2.0 %

Shares of NASDAQ KROS opened at $58.55 on Friday. The company has a market capitalization of $2.37 billion, a PE ratio of -11.24 and a beta of 1.23. The stock’s 50 day moving average price is $59.45 and its 200-day moving average price is $52.27. Keros Therapeutics, Inc. has a twelve month low of $27.31 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business’s revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.33) earnings per share. As a group, research analysts expect that Keros Therapeutics, Inc. will post -5.28 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.